• Ascletis started a global Phase III program for its once-daily oral obesity drug candidate ASC30 following FDA Phase III clearance.
• Two pivotal trials plan to enroll about 4,600 people with obesity or overweight across the U.S., Europe, and Canada, including cohorts with type 2 diabetes.
• Topline Phase III results are expected in Q3 2028, supporting a planned U.S. NDA filing by end-2028 and an EU MAA in early 2029.
• Preclinical work in non-human primates showed its oral GLP-1/GIP/amylin fixed-dose combination drove greater weight loss than a GLP-1/amylin combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12269207), on August 03, 2026, and is solely responsible for the information contained therein.